Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Comments I made in response to Mike Pringle's article on the CMOs
revalidation and relicensing were included in this summary of rapid
but I regret they were edited in such a way as to possibly misguide
about the point I was trying to make.
I commented that study leave budgets were being slashed throughout UK
and as a consequence some doctors were advised to use sponsorship from the
pharmaceutical industry to complete their CME/CPD requirements. I also
that this situation was potentially harmful to patient safety, but the
obscured my point that this harm arises from the lack of study leave
and not from industry sponsorship per se.
Critics of industry sponsorship would make a useful contribution to
resolution of this problem were they to focus their efforts on pressing
provision of adequate central or local NHS funding for CME/CPD so doctors
meet appropriate requirements, thus rendering industry sponsorship and all
perceived problems unnecessary.